Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Withdrawn 1Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myelomonocytic, Juvenile 1Down Syndrome 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 29blinatumomab 19Vincristine 16Specimen Handling 13Methotrexate 13Dexamethasone 13fludarabine 12Prednisone 11Cytarabine 11Biopsy 11Doxorubicin 9Asparaginase 9Rituximab 8Mercaptopurine 8Inotuzumab Ozogamicin 8merphos 7Spinal Puncture 7N,N-dicyclohexyl-isoborneol-10-sulfonamide 7Magnetic Resonance Spectroscopy 7venetoclax 6prednylidene 6dexamethasone acetate 6dexamethasone 21-phosphate 6deltacortene 6azathiopurine 6auricularum 6Etoposide 6Daunorubicin 6Calcium Dobesilate 6pegaspargase 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Burkitt Lymphoma × hydrocortisone hemisuccinate × Clear all
NCT04546399 2025-09-10

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

National Cancer Institute (NCI)

Phase 2 Recruiting
461 enrolled
Lymphoid

Burkitt Lymphoma, Down Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡